BI 1199.248 INBUILD-ON An open label extension trial of the long term safety of nintedanib in patients with progressive fibrosing interstitial lung disease.
Clinical Trial Grant
Administered By
Medicine, Pulmonary, Allergy, and Critical Care Medicine
Awarded By
Boehringer Ingelheim Corporation
Start Date
May 8, 2019
End Date
March 31, 2023
Administered By
Medicine, Pulmonary, Allergy, and Critical Care Medicine
Awarded By
Boehringer Ingelheim Corporation
Start Date
May 8, 2019
End Date
March 31, 2023